On this page
CIITA
class II major histocompatibility complex transactivator
The CIITA gene provides instructions for a protein essential in immune system function, primarily by controlling the activity of major histocompatibility complex (MHC) class II genes. The CIITA gene is central to the body's immune response, directing the production of MHC class II proteins.
CIITA is located on the short (p) arm of chromosome 16, at band 16p13.13. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 16 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The CIITA gene, also known as the class II major histocompatibility complex transactivator, is a critical regulator of the immune system. It encodes a protein that governs the expression of major histocompatibility complex (MHC) class II genes, which are fundamental for an effective immune response. The proper function of the CIITA protein is therefore vital for the body's defence mechanisms against pathogens.
What the gene does
The CIITA protein acts as a master regulator for MHC class II gene transcription, coordinating various proteins to initiate the production of MHC class II proteins. These MHC class II proteins are situated on the surface of specific immune cells, such as lymphocytes, where they present fragments of foreign proteins (peptides) to other immune cells. This presentation is crucial for recognising invaders and triggering an appropriate immune response to eliminate them. The CIITA protein also influences the transcription of MHC class I genes, which are involved in presenting internally derived peptides to immune cells, although it is not their primary regulator. Its role is primarily focused on orchestrating the adaptive immune system's ability to identify and react to external threats.
Video: Genetics 101
Chromosome location
The CIITA gene is located on chromosome 16 at position 16p13.13. This genomic address specifies its precise position within the human genome.
Protein structure
The CIITA protein consists of 1130 amino acids and features several distinct functional regions. Between positions 94 and 132, a segment crucial for the protein's acetyltransferase function can be found. Another stretch, spanning amino acids 270 to 303, lacks stable three-dimensional structure. The protein also includes a NACHT domain (amino acids 414-724) and several Leucine-rich repeat (LRR) regions: LRR 1 (amino acids 985-1008), LRR 2 (amino acids 1016-1037), LRR 3 (amino acids 1045-1066), and LRR 4 (amino acids 1073-1093).
Key variants
Variants within the CIITA gene can alter the function of the encoded protein, leading to a range of health implications. These genetic changes can affect the protein's ability to regulate MHC class II gene expression, thereby compromising immune system function. The clinical impact of a variant depends on its specific nature and location within the gene.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1383dup | p.Ala462fs | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.1518del | p.Gln507fs | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.1615C>T | p.Arg539Ter | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.1962del | p.Ala656fs | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.1962dup | p.Gly655fs | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.2888+1G>A | - | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.2889-1G>T | - | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.2959C>T | p.Gln987Ter | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.632del | p.Pro211fs | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency 1 |
c.682C>T | p.Gln228Ter | Pathogenic | ★★☆☆ | MHC class II deficiency |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the CIITA gene are associated with inherited immune disorders. Bare lymphocyte syndrome type II (BLS II) is a severe immune disorder linked to CIITA dysfunction. This combined immunodeficiency (CID) leaves patients highly vulnerable to recurrent, serious infections because their immune defences are markedly compromised. Variants in CIITA have also been linked to autoimmune Addison disease.
No disease links recorded for this gene in our reference set.
UK clinical status
The CIITA gene is included in several UK NHS national genomic testing panels. It is listed on the 'COVID-19 research' panel and the 'Primary immunodeficiency or monogenic inflammatory bowel disease' panel (R15), both classified as green, indicating that there is strong evidence for the gene's association with these conditions.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the main function of the CIITA gene?
The CIITA gene provides instructions for a protein that primarily controls the activity of major histocompatibility complex (MHC) class II genes. This regulation is crucial for the immune system to recognise and respond to foreign invaders.
What conditions are associated with CIITA gene variants?
Variants in the CIITA gene are primarily associated with bare lymphocyte syndrome type II (BLS II), a severe immune deficiency. They have also been linked to autoimmune Addison disease.
How does CIITA affect the immune system?
The CIITA protein helps activate the production of MHC class II proteins, which are displayed on immune cells. These proteins present fragments of foreign pathogens to other immune cells, initiating a targeted immune response to clear infections.
References
- Ahmed A, Reith W, Puck JM. Novel Mutation in the Class II Transactivator Associated with Immunodeficiency and Autoimmunity. Journal of clinical immunology. 2015. PMID: 26271388
- Devaiah BN, Singer DS. CIITA and Its Dual Roles in MHC Gene Transcription. Frontiers in immunology. 2013. PMID: 24391648
- Gobin SJ, Peijnenburg A, van Eggermond M. The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes. Immunity. 1998. PMID: 9806639
- Bontron S, Steimle V, Ucla C. Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A. Human genetics. 1997. PMID: 9099848
- Martin BK, Chin KC, Olsen JC. Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity. 1997. PMID: 9175837